National Health Investors (NHI) Tops Q4 EPS by 1c, Introduces FY 2026 guidance

National Health Investors (NYSE: NHI) reported Q4 EPS of $0.80, $0.01 better than the analyst estimate of $0.79. Revenue for the quarter came in at $105.8 million versus the consensus estimate of $73.55 million.

NHI is introducing its 2026 annual guidance range which includes the following:

NAREIT FFO per diluted share range of $4.94 - $4.99;

Normalized FFO per diluted share range of $4.94 - $4.99; and

Normalized FAD range of $248.9 million - $251.4 million

For earnings history and earnings-related data on National Health Investors (NHI) click here.

You May Also Be Interested In

• Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
• MapLight Therapeutics, Inc. (MPLT) Misses Q2 EPS by 33c
• CaliberCos Inc (CWD) Misses Q2 EPS by 43c; Offers Guidance